Neurocrine Biosciences (Brazil) Investor Sentiment

N1BI34 Stock   35.67  0.00  0.00%   
About 67% of Neurocrine Biosciences' investor base is looking to short. The analysis of current outlook of investing in Neurocrine Biosciences suggests that many traders are alarmed regarding Neurocrine Biosciences' prospects. The current market sentiment, together with Neurocrine Biosciences' historical and current headlines, can help investors time the market. In addition, many technical investors use Neurocrine Biosciences stock news signals to limit their universe of possible portfolio assets.
  
a day ago at news.google.com         
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Has 94.48 Million Stake in Neurocrine Biosciences, Inc. - ...
Google News at Macroaxis
over three weeks ago at news.google.com         
Implied Volatility Surging for Neurocrine Biosciences Stock Options - Yahoo Finance
Google News at Macroaxis
over a month ago at news.google.com         
The Play On Neurocrine Biosciences - Seeking Alpha
Google News at Macroaxis
over a month ago at news.google.com         
Perceptive Advisors LLC Cuts Holdings in Neurocrine Biosciences, Inc. - MarketBeat
Google News at Macroaxis
over a month ago at news.google.com         
BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp Acquires 7,326 Shares of Neurocrine Biosciences, Inc. - ...
Google News at Macroaxis
over a month ago at news.google.com         
Neurocrine Biosciences, Inc. Shares Bought by Dimensional Fund Advisors LP - MarketBeat
Google News at Macroaxis
over a month ago at news.google.com         
Neurocrine Biosciences stock impacted by warnings in Cobenfy label, says Mizuho - Investing.com Sout...
Google News at Macroaxis
over two months ago at news.google.com         
Neurocrine Biosciences Stock Quotes, Forecast and News Summary - Benzinga
Google News at Macroaxis
over two months ago at news.google.com         
Why Neurocrine Biosciences Stock Was Tumbling This Week - sharewise
Google News at Macroaxis
over two months ago at news.google.com         
Neurocrine Biosciences to Participate at Investor Conferences in September - StockTitan
Google News at Macroaxis
over three months ago at news.google.com         
Neurocrine Biosciences, Inc. Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Google News at Macroaxis
over three months ago at news.google.com         
Neurocrine Biosciences, Inc. Director Gary A. Lyons Sells 11,570 Shares - Defense World
Google News at Macroaxis
over three months ago at news.google.com         
Neurocrine Biosciences Stock Charts Show Upside Breakout - TheStreet
Google News at Macroaxis
over three months ago at news.google.com         
Acadian Asset Management LLC Sells 27,778 Shares of Neurocrine Biosciences, Inc. - Defense World
Google News at Macroaxis
over three months ago at news.google.com         
Neurocrine Biosciences Given Overweight Rating at Cantor Fitzgerald - MarketBeat
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Neurocrine Biosciences that are available to investors today. That information is available publicly through Neurocrine media outlets and privately through word of mouth or via Neurocrine internal channels. However, regardless of the origin, that massive amount of Neurocrine data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Neurocrine Biosciences news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Neurocrine Biosciences relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Neurocrine Biosciences' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Neurocrine Biosciences alpha.

Neurocrine Biosciences Performance against Dow Jones

 Price Growth (%)  
       Timeline  

Complementary Tools for Neurocrine Stock analysis

When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
CEOs Directory
Screen CEOs from public companies around the world
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets